[pending] RAPIDOL (BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE)
Pending LLM rewrite. Source: FDA_DRUG D-0429-2025.
- Product
- RAPIDOL — RAPIDOL (BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE)
- Category
- Drug
- Distribution
- 2 states
Category
FDA recalls of prescription and over-the-counter drugs.
FDA drug recalls cover prescription medicines, over-the-counter products, biologic and gene therapies, and active pharmaceutical ingredients (the raw drug substances that manufacturers compound into finished products). Recall classifications follow the same Class I / II / III system as food, and most published recalls are Class II — the product is unlikely to cause permanent harm but doesn't meet specification.
The most common reasons for a drug recall are out-of-specification potency or dissolution (the active ingredient is present in too high or too low a dose), microbial contamination, particulate matter in injectables, mix-ups during packaging where bottles end up with the wrong tablets, and nitrosamine impurities in certain drug classes. Many drug recalls are at the lot level — the manufacturer's whole product line is still safe to use, but specific production lots are pulled.
If a recall affects your medication: don't stop taking it on your own. Call your prescriber or pharmacist before doing anything. Stopping a prescribed drug abruptly can be more dangerous than the issue prompting the recall. Most drug-recall remedies route through the dispensing pharmacy, who'll either swap your supply for an unaffected lot or coordinate a refund with the manufacturer.
Pending LLM rewrite. Source: FDA_DRUG D-0429-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0442-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0432-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0446-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0427-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0430-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0428-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0431-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0424-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0423-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0441-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0437-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0434-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0422-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0435-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0433-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0443-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0426-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0439-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0440-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0445-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0444-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0438-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0418-2025.
Pending LLM rewrite. Source: FDA_DRUG D-0420-2025.
Looking for a different category? Browse all recalls.